EUVIMEDEUVIMED entdecken
Crossref

Colon-Targeted β 3 -Adrenoceptor Agonist Mirabegron Enhances Anticolitic Potency of the Drug via Potentiating the Nrf2-HO-1 Pathway

Jaejeong Kim, Changyu Kang, Jin-Wook Yoo iD, In-Soo Yoon iD, Yunjin Jung iD

Molecular Pharmaceutics · 05.05.2025 · 22 (5) · 2431-2445

DOI: 10.1021/acs.molpharmaceut.4c01041 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 17.04.2025. Verfasst von Jaejeong Kim und 4 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea. Hauptthemen laut MEDLINE: Thiazoles, NF-E2-Related Factor 2, Colon, Adrenergic beta-3 Receptor Agonists. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 63 Literaturangaben. Gefördert von: National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The selective agonist of β3-adrenergic receptor mirabegron (MBG), clinically used to treat overactive bladders, exerts beneficial effects in animal models of colitis. Here, we aimed to enhance the therapeutic activity and safety of MBG as an anticolitic drug by implementing colon-targeted drug delivery using a prodrug approach. MBG was azo-linked with salicylic acid (SA) to yield SA-conjugated MBG (MAS), which was conjugated with aspartic acid (Asp) and glutamic acid (Glu) to yield more hydrophilic derivatives: Asp-conjugated MAS (MAS-Asp) and Glu-conjugated MAS (MAS-Glu). MBG derivatives reduced the distribution coefficient and cell permeability of MBG, which were greater with the amino acid-conjugated MAS than with MAS. MBG derivatives were cleaved to release MBG in the cecal contents. Upon oral gavage, compared with MBG, MBG derivatives delivered greater amounts of MBG to the cecum while limiting the systemic absorption of MBG, and the amino acid-conjugated MAS exhibited a greater performance than MAS. In a rat colitis model, MBG derivatives were more effective than MBG in ameliorating colonic damage and inflammation, and the amino acid-conjugated MAS was more potent than MAS. MAS-Glu was therapeutically superior to sulfasalazine, a current drug to treat inflammatory bowel disease, against rat colitis. Moreover, MBG activated the anti-inflammatory nuclear factor erythroid 2-related factor 2 (Nrf2)-hemeoxygenase (HO)-1 pathway in inflamed colonic tissue, and the MAS-Glu-mediated amelioration of colitis was significantly compromised by an HO-1 inhibitor. Taken together, colon-targeted delivery of MBG may enhance the anticolitic activity, reduce the risk of systemic side effects of MBG, and elicit the therapeutic effects, at least partly by activating the Nrf2-HO-1 pathway.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThiazolesNF-E2-Related Factor 2ColonAdrenergic beta-3 Receptor AgonistsColitisAcetanilidesHeme Oxygenase-1AnimalsRatsMaleRats, Sprague-DawleySignal TransductionDisease Models, AnimalHumansDrug Delivery SystemsMice

Stichwörter der Autor:innen

beta-3 adrenergic receptorcolon-targeted drug deliveryinflammatory bowel diseasemirabegronnuclear factor erythroid 2-related factor 2prodrug

Substanzen

ThiazolesNF-E2-Related Factor 2mirabegronAdrenergic beta-3 Receptor AgonistsAcetanilidesHeme Oxygenase-1

Autor:innen und Institutionen

  • College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea.
  • Research Institute for Drug Development, Pusan National University, Busan 46241, Republic of Korea.

ORCID-Profile: Jin-Wook Yoo, In-Soo Yoon, Yunjin Jung

Förderung

  • National Research Foundation of Korea

Zitieren

APA

Kim, J., Kang, C., Yoo, J. W., Yoon, I. S., & Jung, Y. (2025). Colon-Targeted β 3 -Adrenoceptor Agonist Mirabegron Enhances Anticolitic Potency of the Drug via Potentiating the Nrf2-HO-1 Pathway. Molecular Pharmaceutics, 22(5), 2431-2445. https://doi.org/10.1021/acs.molpharmaceut.4c01041

Vancouver

Kim J, Kang C, Yoo JW, Yoon IS, Jung Y. Colon-Targeted β 3 -Adrenoceptor Agonist Mirabegron Enhances Anticolitic Potency of the Drug via Potentiating the Nrf2-HO-1 Pathway. Molecular Pharmaceutics. 2025;22(5):2431-2445. doi:10.1021/acs.molpharmaceut.4c01041

BibTeX
@article{Kim2025,
  author = {Kim, Jaejeong and Kang, Changyu and Yoo, Jin-Wook and Yoon, In-Soo and Jung, Yunjin},
  title = {Colon-Targeted β 3 -Adrenoceptor Agonist Mirabegron Enhances Anticolitic Potency of the Drug via Potentiating the Nrf2-HO-1 Pathway},
  journal = {Molecular Pharmaceutics},
  year = {2025},
  volume = {22},
  number = {5},
  pages = {2431--2445},
  doi = {10.1021/acs.molpharmaceut.4c01041}
}
Kostenlos starten →